Across TCGA pan-cancer cohorts, CD2AP Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD2AP data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CD2AP Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CD2AP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, PRAD, and HNSC are the cancer types where CD2AP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.922	0.437	.024	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	OS	Median	All	0.242	0.661	.039	6	view →
SKCM	DFS	Median	III,IV	0.122	0.601	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CD2AP tumor-vs-normal RNA expression · all CD2AP data types